Download Files:
Aflibercept
SKU
HY-108801-1 mg
Category Inhibitory Antibodies
Tags Metabolic Disease; Cardiovascular Disease, Protein Tyrosine Kinase/RTK, VEGFR
$530 – $1,950
Products Details
Product Description
– Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease[1][2][3].
Web ID
– HY-108801
Storage Temperature
– Store at 4°C for 2 years, do not freeze
Shipping
– Isolate blue ice and the product with bubble pack to avoid direct contact
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– N/A
References
– [1]Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct;98(10):1448-52.|[2]Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52(8):2637-2648.|[3]Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep;42(9):1437-1448.
CAS Number
– 862111-32-8
Molecular Weight
– N/A
Compound Purity
– 97.0
SMILES
– [Aflibercept]
Clinical Information
– Launched
Research Area
– Metabolic Disease; Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– VEGFR
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Inhibitory Antibodies
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.